Home / Market News / $VKTX

$VKTX news and market catalysts

The 23 most recent market catalysts affecting $VKTX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

23 catalysts 8 high impact 7 bullish 8 bearish Biotechnology
Nov 15, 2026 Corporate Catalyst Bullish Impact 90
Viking Therapeutics Reports Renewed Takeover Interest
Viking Therapeutics experienced a significant share price increase following reports of renewed takeover interest. This speculation is primarily driven by the company's promising p…
Oct 30, 2026 Corporate Catalyst Bearish Impact 75
Viking Therapeutics Reports Third Quarter 2026 Financial Results and Clinical Trial Progress
Viking Therapeutics reported a substantial net loss for Q3 2026, driven by high R&D and clinical trial costs. This is expected for a pre-revenue biotechnology company heavily inves…
Oct 28, 2026 Corporate Catalyst Neutral Impact 75
Viking Therapeutics Reports Third Quarter 2026 Financial Results
Viking Therapeutics announced its Q3 2026 financial results, revealing an increased net loss driven by higher operational expenses, which could be a short-term negative for investo…
Oct 15, 2026 Corporate Catalyst Neutral Impact 65
UBS Initiates Coverage On Viking Therapeutics with Buy Rating, Announces Price Target of $94
UBS analyst Joon Lee initiated coverage on Viking Therapeutics (VKTX) with a 'Buy' rating and a $94 price target. This is a positive development for VKTX as new analyst coverage, e…
Oct 14, 2026 Corporate Catalyst Neutral Impact 85
Viking Therapeutics Initiates SUNRISE Phase 3 Clinical Program For Oral VK2735 Dual Agonist Of GLP-1 And Glucose-Dependent Insulinotropic Polypeptide Receptors
Viking Therapeutics has announced the initiation of its SUNRISE Phase 3 clinical program for oral VK2735, a dual GLP-1 and GIP receptor agonist. This is a critical development as i…
Oct 13, 2026 Market Technicals Neutral Impact 55
10 Health Care Stocks With Whale Alerts In Today’s Session
This filing details 'whale alerts' in the options market for several health care companies, indicating large-scale trading activity by institutional investors. This matters because…
Oct 6, 2026 Corporate Catalyst Neutral Impact 65
Viking Therapeutics Begins Exploratory Oral Maintenance Dosing Study Of VK2735, Its Dual Agonist Of Glucagon-Like Peptide 1 And Glucose-Dependent Insulinotropic Polypeptide Receptors
Viking Therapeutics announced the start of Part 2 of its maintenance dosing study for VK2735, an obesity drug. This part of the study will investigate various oral and additional s…
Sep 24, 2026 Corporate Catalyst Bearish Impact 75
Why Is Viking Therapeutics Stock Trading Down Thursday?
Viking Therapeutics' stock plummeted by 15% following the announcement of an upsized public offering of common stock and convertible senior notes. This move, while securing signifi…
Sep 24, 2026 Corporate Catalyst Bearish Impact 75
Viking Therapeutics shares are trading lower after the company announced the pricing of its $500 million offering.
The $500 million stock offering by Viking Therapeutics is a significant corporate catalyst. While it provides the company with substantial capital for R&D, clinical trials, or othe…
Sep 24, 2026 Corporate Catalyst Neutral Impact 75
Viking Therapeutics Prices Concurrent Public Offerings Of 7,857,143 Shares At $35/Shr And $225M Aggregate Principal Amount Of 2.00% Convertible Senior Notes Due 2032
Viking Therapeutics priced concurrent public offerings, selling 7,857,143 shares at $35.00 per share and $225 million in 2.00% convertible senior notes due 2032. This represents a …
Sep 23, 2026 Corporate Catalyst Bearish Impact 75
Viking Therapeutics Stock Drops In After Hours on Proposed Public Offerings
Viking Therapeutics is undertaking a significant capital raise, proposing to offer $200 million in common stock and $200 million in convertible senior notes. This action is typical…
Sep 23, 2026 Corporate Catalyst Bullish Impact 95
QUICK SPARK: Viking Therapeutics Stock Gains 40% in 2 Days
Viking Therapeutics' stock surged over 40% in two days following the announcement of positive results for its lead obesity drug candidate, VK2735. The drug demonstrated superior we…
Sep 23, 2026 Corporate Catalyst Neutral Impact 85
Viking Therapeutics Announces $200M Common Stock And $200M Convertible Senior Notes Due 2032; Proceeds To Fund VK2735, VK3019 Clinical Development And General Corporate Purposes
Viking Therapeutics is raising a substantial $400 million through a combination of common stock and convertible senior notes. This capital raise, while providing crucial funding fo…
Sep 23, 2026 Corporate Catalyst Bullish Impact 55
Truist Securities Maintains Buy on Viking Therapeutics, Raises Price Target to $87
Truist Securities analyst Joon Lee has updated their outlook on Viking Therapeutics, maintaining a 'Buy' rating and raising the price target from $83 to $87. This action signals a …
Sep 22, 2026 Corporate Catalyst Bullish Impact 95
Weight Loss Drug: Viking Therapeutics Says Lead Obesity Drug Shows Weight Retention with Less Frequent Dosing
Viking Therapeutics released highly anticipated positive topline results for its lead obesity drug, VK2735, specifically from its maintenance trial. The drug demonstrated robust we…
Sep 22, 2026 Corporate Catalyst Bullish Impact 95
Viking Therapeutics shares are trading higher after the company announced top-line results from the maintenance study of VK2735.
The positive top-line results for VK2735 are a major corporate catalyst for Viking Therapeutics. This success de-risks the drug's development pathway and significantly increases it…
Sep 22, 2026 Corporate Catalyst Bullish Impact 85
Market-Moving News for September 22nd
This filing compiles three separate, significant corporate catalysts. Vicor's raised Q3 revenue guidance suggests improved financial performance, which is a positive signal for inv…
Sep 22, 2026 Corporate Catalyst Bullish Impact 92
Viking Therapeutics Announces Top-line Results From Maintenance Study Of VK2735, A Dual Agonist Of GLP-1 And Glucose-Dependent Insulinotropic Polypeptide Receptors; 22% Placebo-Adjusted Weight Loss Reported At Week 33 Following Weekly Dosing Of VK2735At 17.5 MG; No Plateau Observed
Viking Therapeutics released highly positive top-line results from its VK2735 maintenance study, showing a 22% placebo-adjusted weight loss at week 33 with no plateau observed. Cru…
Sep 16, 2026 Market Technicals Neutral Impact 65
10 Health Care Stocks Whale Activity In Today’s Session
This 8-K filing highlights 'whale' options trading activity in ten healthcare stocks, indicating that large, sophisticated investors are making significant bets on these companies.…
Sep 15, 2026 Market Technicals Bearish Impact 55
What's Going On With the Dip in Viking Therapeutics Stock?
Viking Therapeutics (VKTX) shares are down today, but the filing attributes this to a general 'risk-off' market session, with the Nasdaq and S&P 500 also declining. This suggests t…
Aug 11, 2026 Corporate Catalyst Bearish Impact 60
JP Morgan Maintains Overweight on Viking Therapeutics, Lowers Price Target to $65
JP Morgan analyst Hardik Parikh maintained an 'Overweight' rating on Viking Therapeutics (VKTX), signaling a continued belief in the company's fundamental strength and future growt…
Jul 30, 2026 Corporate Catalyst Bearish Impact 75
Viking Therapeutics Stock Moves Lower: What's Going On?
Viking Therapeutics (VKTX) shares experienced a decline despite reporting a narrower second-quarter loss than anticipated. This negative market reaction appears to be driven by a s…
Jul 29, 2026 Corporate Catalyst Bearish Impact 75
Viking Therapeutics Q2 EPS $(1.10) Beats $(1.25) Estimate
Viking Therapeutics (VKTX) announced a Q2 loss of $(1.10) per share, which, while still a loss, surpassed analyst expectations of $(1.25). This 'beat' on the bottom line is general…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.